Kyverna Therapeutics Inc.

1.99
-0.16 (-7.44%)
At close: Apr 03, 2025, 3:59 PM
1.97
-0.76%
After-hours: Apr 03, 2025, 04:05 PM EDT

Company Description

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases.

Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.

The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases.

In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis.

Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases.

The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019.

Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Kyverna Therapeutics Inc.
Kyverna Therapeutics Inc. logo
Country United States
IPO Date Feb 9, 2024
Industry Biotechnology
Sector Healthcare
Employees 112
CEO Ryan Jones M.B.A.

Contact Details

Address:
5980 Horton Street
Emeryville, California
United States
Website https://kyvernatx.com

Stock Details

Ticker Symbol KYTX
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001994702
CUSIP Number 501976104
ISIN Number US5019761049
Employer ID 83-1365441
SIC Code 2836

Key Executives

Name Position
Ryan Jones M.B.A. Chief Financial Officer
Cara Bauer Ph.D. Chief Human Resources Officer
Dan Maziasz Chief Business Officer
Dr. Naji H. Gehchan M.B.A., M.D. Chief Medical & Development Officer
Dr. Tom Van Blarcom Ph.D. Senior Vice President & Head of Research
Tracy Rossin Senior Vice President of Corporate Affairs & Communications and Investor Relations

Latest SEC Filings

Date Type Title
Mar 27, 2025 8-K Current Report
Mar 27, 2025 S-8 Filing
Mar 27, 2025 S-3 Filing
Mar 27, 2025 10-K Annual Report
Mar 27, 2025 8-K Current Report
Feb 19, 2025 4 Filing
Jan 24, 2025 4 Filing
Jan 24, 2025 3 Filing
Jan 21, 2025 8-K Current Report
Jan 13, 2025 8-K Current Report